Allergan Expands Access to IUDs for Millions of Underserved Women in the US by Announcing Agreement with Apexus for Nationwide Distribution of Liletta 52 mg
Allergan has announced an agreement to make Liletta available to the safety-net provider locations that Apexus, the 340B Drug Pricing Program Prime Vendor serves.
Sept. 10, 2015
/PRNewswire/ -- Allergan plc, a leading global pharmaceutical company, has announced an agreement to make LILETTA
available to the safety-net provider locations that Apexus, the 340B Drug Pricing Program Prime Vendor serves. The agreement provides LILETTA discounted per unit price to all public health clinics and organizations that participate in the 340B Prime Vendor Program (PVP) and expands access to IUDs for millions of underserved women throughout
the United States
who may not have been able to afford one.
"We applaud the leadership that Apexus has exhibited to the health care industry as the prime vendor for the 340B Drug Pricing Program," said
, Vice President of
. "Together with Medicines360, we are committed to increasing access and reducing cost barriers to IUD use, and our partnership with Apexus plays a key role in fulfilling that commitment."
"We are committed to helping 340B entities deliver health care services to underserved patients and enabling them to treat more patients in need through discounted pharmaceuticals and value-added services," said
, Vice President of Marketing and Customer Service for Apexus. "By making LILETTA more accessible to all women regardless of insurance coverage 340B helps protect health and empower patients. We are proud to do our part as the 340B prime vendor."
Since the product became available in
, thousands of LILETTA IUDs have been shipped to provider locations in 49 states, including state and county health departments, family planning centers, and Indian Health Service clinics.